国投证券医药产业链数据库之：血制品批签发，1-8 月白蛋白批签发同比小幅增长，静丙略有下滑

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the pharmaceutical industry [2]. Core Insights - The report highlights a slight increase in the batch issuance of domestic albumin and a decrease in immunoglobulin products, indicating mixed performance across different blood products [1][7]. - Key companies to watch include TianTan Biotech, PaiLin Biotech, BoYa Biotech, Shanghai Raist, Hualan Biological, WeiGuang Biotech, and BoHui Innovation [2]. Summary by Sections 1. Overview of Blood Product Batch Issuance - In the first eight months of 2024, domestic albumin batch issuance totaled 1,123 batches, a 5% year-on-year increase, while imported albumin reached 2,417 batches, a 6% increase [1][7]. - For immunoglobulin products, the total batch issuance for the same period was 865 for IVIG (down 10%) and 58 for IMIG (down 2%) [1][7]. 2. Albumin - The annual batch issuance of albumin has shown a steady growth trend with a CAGR of 11.5% from 2011 to 2023, with domestic albumin growing at 5.5% and imported at 17.3% [9]. - In August 2024, domestic albumin saw a batch issuance of 135 (down 6%), while imported albumin had 306 (down 19%) [1][7]. 3. Immunoglobulin (IVIG & IMIG) - The report notes that IVIG has a long-term growth potential despite a slight decrease in batch issuance in August 2024 [15]. - The total batch issuance for IVIG in the first eight months of 2024 was 865, while IMIG was 58 [15][19]. 4. Specific Immunoglobulins - For specific immunoglobulins, the report indicates a mixed performance: hepatitis B immunoglobulin (乙免) batch issuance increased by 29%, while tetanus immunoglobulin (破免) decreased by 10% [1][7]. - The rabies immunoglobulin (狂免) saw a significant increase of 36% in batch issuance, while the group immunoglobulin (组免) increased by 30% [1][7]. 5. Coagulation Factors - The report indicates that the batch issuance of coagulation factors has shown varied trends, with human coagulation factor VIII increasing by 23% and human coagulation factor IX increasing by 64% in the first eight months of 2024 [1][31]. - The total batch issuance for coagulation factors in this period was 376 for factor VIII, 176 for PCC, and 190 for fibrinogen [31][36].